AtriCure Inc (Nasdaq:ATRC) on Tuesday reported the completion of the acquisition of SentreHEART Inc for an undisclosed amount.

Based in Redwood City, California, SentreHEART is a privately-owned medical device company committed to clinical evidence development and is currently sponsoring the FDA-approved prospective, multi-centre, randomized controlled trial (aMAZE Trial).

Founded in 2005, SentreHEART has developed innovative technology for remote delivery of suture for closure of anatomic structures including the left atrial appendage (LAA).

According to AtriCure Inc, it provides innovative technologies for the treatment of Afib and related conditions. The electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications.